{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:40:02Z","timestamp":1759124402284,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.radonc.2018.06.033","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T13:21:15Z","timestamp":1530969675000},"page":"507-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy"],"prefix":"10.1016","volume":"129","author":[{"given":"Everett J.","family":"Moding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saul A.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2018.06.033_b0005","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2018.06.033_b0010","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International prognostic score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0015","doi-asserted-by":"crossref","first-page":"903","DOI":"10.7326\/0003-4819-120-11-199406010-00002","article-title":"Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study","volume":"120","author":"Fabian","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.radonc.2018.06.033_b0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood.V59.3.455.455","article-title":"The management of stage I-II Hodgkin\u2019s disease with irradiation alone or combined modality therapy: the Stanford experience","volume":"59","author":"Hoppe","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2018.06.033_b0025","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.1987.5.7.1041","article-title":"Stage I to IIB Hodgkin\u2019s disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy","volume":"5","author":"Crnkovich","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0360-3016(01)01525-5","article-title":"Mantle irradiation alone for pathologic stage I and II Hodgkin\u2019s disease: long-term follow-up and patterns of failure","volume":"50","author":"Liao","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.06.033_b0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/0003-4819-114-5-361","article-title":"Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group","volume":"114","author":"Henry-Amar","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.radonc.2018.06.033_b0040","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/0003-4819-79-3-376","article-title":"Combination chemotherapy in advanced Hodgkin\u2019s disease. Induction and maintenance of remission","volume":"79","author":"Frei","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.radonc.2018.06.033_b0045","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1097-0142(197808)42:2+<1001::AID-CNCR2820420723>3.0.CO;2-Z","article-title":"Patterns of relapse in advanced Hodgkin\u2019s disease treated with combination chemotherapy","volume":"42","author":"Young","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2018.06.033_b0050","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.1991.9.12.2193","article-title":"Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin\u2019s disease treated with alternating chemotherapy combinations","volume":"9","author":"Yahalom","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0055","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin\u2019s lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2018.06.033_b0060","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.2009.26.0323","article-title":"Consolidation radiotherapy in patients with advanced Hodgkin\u2019s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519)","volume":"28","author":"Johnson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0065","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: a systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0070","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0075","first-page":"630","article-title":"Stanford V and radiotherapy for locally extensive and advanced Hodgkin\u2019s disease: mature results of a prospective clinical trial","volume":"20","author":"Horning","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0080","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0085","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/annonc\/mdp337","article-title":"Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience","volume":"21","author":"Edwards-Bennett","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0090","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2000.18.5.972","article-title":"Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin\u2019s disease: Eastern Cooperative Oncology Group pilot study E1492","volume":"18","author":"Horning","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0095","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin\u2019s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244","volume":"27","author":"Hoskin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0100","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0105","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1998.16.3.818","article-title":"Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin\u2019s disease. International Database on Hodgkin\u2019s Disease Overview Study Group","volume":"16","author":"Loeffler","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0110","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2018.06.033_b0115","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","article-title":"Second malignancy risk associated with treatment of Hodgkin\u2019s lymphoma: meta-analysis of the randomised trials","volume":"17","author":"Franklin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0120","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2018.06.033_b0125","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin\u2019s lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0130","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1002\/cncr.23081","article-title":"Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma","volume":"110","author":"Hodgson","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2018.06.033_b0135","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2018.06.033_b0140","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V126.23.579.579","article-title":"Advanced stage classical Hodgkin lymphoma patients with a negative PET-scan following treatment with ABVD have excellent outcomes without the need for consolidative radiotherapy regardless of disease bulk at presentation","volume":"126","author":"Savage","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2018.06.033_b0145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.1994.12.2.279","volume":"12","author":"Somers","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.06.033_b0150","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018333486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018333486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:07:09Z","timestamp":1759122429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814018333486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0167814018333486"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2018.06.033","relation":{},"ISSN":["0167-8140"],"issn-type":[{"type":"print","value":"0167-8140"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2018.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}